Provided by Tiger Trade Technology Pte. Ltd.

Iovance Biotherapeutics, Inc.

8.44
+0.38004.71%
Pre-market: 8.460.0200+0.24%07:02 EDT
Volume:11.91M
Turnover:99.59M
Market Cap:3.82B
PE:-11.96
High:8.48
Open:8.16
Low:8.03
Close:8.06
52wk High:9.36
52wk Low:1.76
Shares:452.97M
Float Shares:394.00M
Volume Ratio:0.49
T/O Rate:3.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7058
EPS(LYR):-1.0941
ROE:-40.36%
ROA:-20.31%
PB:5.19
PE(LYR):-7.71

Loading ...

US FDA Approves Replimune's Skin Cancer Drug

Reuters
·
Aug 07

Iovance (IOVA) Stock Soars After Better-Than-Expected Q2 Results

Benzinga Earnings
·
Aug 07

U.S. Stocks on the MOVE-Ralph Lauren, Sempra, Parker-Hannifin, Lincoln International

Reuters
·
Aug 07

Analysts’ Opinions Are Mixed on These Healthcare Stocks: VistaGen Therapeutics (VTGN), Iovance Biotherapeutics (IOVA) and Aurinia Pharmaceuticals (AUPH)

TIPRANKS
·
Aug 06

Iovance Biotherapeutics up over 37%, on Pace for Largest Percent Increase Since June 2016

Dow Jones
·
Aug 06

Iovance Biotherapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Iovance Publishes Corporate Presentation Highlighting Amtagvi TIL Therapy Rollout and Pipeline Expansion in Solid Tumors

Reuters
·
Aug 06

Iovance Gains After Q2 Revenue Beat

Reuters
·
Aug 06

Iovance Q2 2026 Earnings: Amtagvi Drives 66% Revenue Growth and a Narrower Loss

TradingKey
·
Aug 06

Earnings Flash (IOVA) Iovance Biotherapeutics Posts Q2 Loss $0.11 a Share, vs. FactSet Est of $0.13 Loss

MT Newswires Live
·
Aug 06

Iovance Biotherapeutics Shares Rise 13.4% Premarket After Q2 Revenue Beat

THOMSON REUTERS
·
Aug 06

Iovance Q2 Operating Loss Narrows to $51.91 Million; Revenue Rises 66% Year over Year to $99.31 Million

Reuters
·
Aug 06

Iovance Biotherapeutics Q2 EPS $(0.11) Beats $(0.14) Estimate, Sales $99.313M Beat $87.832M Estimate

Benzinga Earnings
·
Aug 06

Iovance Biotherapeutics - Reviewing Fy2026 Revenue Guidance of $350 Mln to $370 Mln

THOMSON REUTERS
·
Aug 06

Iovance Biotherapeutics Q2 Revenue USD 99.313 Million

THOMSON REUTERS
·
Aug 06

Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99m, Business Achievements, and Corporate Updates

THOMSON REUTERS
·
Aug 06

Iovance Biotherapeutics (IOVA) Is Down 18.4% After Early Amtagvi Rollout Update - Has The Bull Case Changed?

Simply Wall St.
·
Aug 03

Iovance Biotherapeutics Schedules Second-quarter Results Conference Call

Reuters
·
Jul 30

Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026

GlobeNewswire
·
Jul 30

Iovance Biotherapeutics (IOVA) Rallies On Undervalued Claims, Is The Market Still Missing Fair Value?

Simply Wall St.
·
Jul 25